🔬 The acquisition allows Ascend to support customers from research to commercialization and adds to their experienced gene therapy team.
🤝 Beacon Therapeutics will continue to work with Ascend to advance their sight-saving therapies.
👁️ Beacon Therapeutics currently has three ocular gene therapy products in their portfolio.
Introduction:
Ascend Advanced Therapies has acquired Beacon Therapeutics’ CMC team and GMP facility in Florida, along with a long-term partnership to continue manufacturing Beacon’s gene therapy products. This acquisition will allow Ascend to support customers from research through commercialization and expand their gene therapy manufacturing capabilities.
- Ascend Advanced Therapies has acquired Beacon Therapeutics’ CMC team and GMP facility in Alachua, FL.
- The acquisition includes a long-term partnership to continue manufacturing Beacon’s gene therapy products.
- Ascend aims to support customers from research through commercialization and expand their gene therapy manufacturing capabilities.
- Beacon Therapeutics focuses on developing ocular gene therapy products to address retinal disorders.
Conclusion:
This acquisition by Ascend Advanced Therapies of Beacon Therapeutics’ CMC team and GMP facility, along with the long-term partnership, will enable Ascend to expand their gene therapy manufacturing capabilities and support customers from research through commercialization. This strategic move will also help Beacon Therapeutics secure GMP drug product supply for its late-stage clinical asset and continue advancing its sight-saving therapies. Overall, this acquisition strengthens the gene therapy landscape and supports the development of innovative treatments for retinal disorders.
